Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data

Fabrizio Nelli , Enzo Maria Ruggeri , Antonella Virtuoso , Diana Giannarelli , Armando Raso , Federica Natoni , Gloria Pessina , Daniele Remotti , Mario Giovanni Chilelli , Carlo Signorelli , Agnese Fabbri

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002287

PDF (2233KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002287 DOI: 10.37349/etat.2025.1002287
Original Article
research-article
Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data
Author information +
History +
PDF (2233KB)

Abstract

Aim: The interaction of concomitant benzodiazepine (BZD) exposure during immune checkpoint blockade has not been comprehensively investigated to date. This research aimed to determine the influence of BZD intake on the survival outcomes of patients with metastatic non-small-cell lung cancer (NSCLC) receiving pembrolizumab-based therapies.

Methods: We included consecutive patients with advanced NSCLC who were given frontline pembrolizumab, whether as exclusive therapy or combined with platinum-based chemotherapy. The classification of BZD relied on the molecular composition, distinguishing between N-substituted and N-unsubstituted compounds.

Results: During the time frame from April 2018 to May 2023, we enrolled 258 patients, 156 (60.5%) and 102 (39.5%) of whom received pembrolizumab alone or the combination regimen, respectively. We identified 108 (41.8%) exposed patients (BZD cohort) in comparison to all others (no-BZD cohort). After applying propensity-score matching, 108 cases were relevant for each cohort. After a median follow-up of 16.3 [95% confidence interval (CI) 13.1–19.7] months, univariate analysis revealed no significant differences in terms of progression-free survival (PFS) or overall survival (OS) between BZD cohorts. However, patients exposed toN-substituted compounds had significantly longer PFS and OS than those who did not take BZD. Conversely, patients exposed to N-unsubstituted compounds experienced significantly shortened OS. Multivariate testing showed that taking unspecified BZD had no impact on PFS or OS, while N-substituted BZD exposure correlated independently with longer PFS [hazard ratio (HR) 0.52 (95% CI 0.34–0.79); P = 0.002] and OS [HR 0.58 (95% CI 0.38–0.88);P < 0.001]. In contrast, N-unsubstituted BZD intake had worsening effects on OS [HR 1.92 (95% CI 1.20–3.06); P = 0.006].

Conclusions: BZD exposure may impact the efficacy of immune checkpoint inhibitors in patients with advanced NSCLC. The specific composition may influence the choice among different compounds.

Keywords

Concomitant medications / non-small-cell lung cancer / immune checkpoint blockade / pembrolizumab / chemotherapy / first-line therapy / benzodiazepines / efficacy

Cite this article

Download citation ▾
Fabrizio Nelli, Enzo Maria Ruggeri, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Federica Natoni, Gloria Pessina, Daniele Remotti, Mario Giovanni Chilelli, Carlo Signorelli, Agnese Fabbri. Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002287 DOI:10.37349/etat.2025.1002287

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Hanahan D, Monje M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell. 2023; 41: 573-80.

[2]

Li TJ, Jiang J, Tang YL, Liang XH. Insights into the leveraging of GABAergic signaling in cancer therapy. Cancer Med. 2023; 12: 14498-510.

[3]

Yang Y, Ren L, Li W, Zhang Y, Zhang S, Ge B, et al. GABAergic signaling as a potential therapeutic target in cancers. Biomed Pharmacother. 2023; 161: 114410.

[4]

Bhandage AK, Barragan A. GABAergic signaling by cells of the immune system: more the rule than the exception. Cell Mol Life Sci. 2021; 78: 5667-79.

[5]

Zhang B, Vogelzang A, Miyajima M, Sugiura Y, Wu Y, Chamoto K, et al. B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity. Nature. 2021; 599: 471-6.

[6]

Huang D, Wang Y, Thompson JW, Yin T, Alexander PB, Qin D, et al. Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. Nat Cell Biol. 2022; 24: 230-41.

[7]

Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002; 300: 2-8.

[8]

Nausea and Vomiting Related to Cancer Treatment (PDQ®)-Health Professional Version [Internet]. [Cited 2024 Sep 30]. Available from: https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq

[9]

Yasuda S, Sugano K, Matsuda Y, Kako J, Takagi Y, Watanabe H, et al. Systematic review and meta-analysis of the efficacy of benzodiazepines for dyspnea in patients with cancer. Jpn J Clin Oncol. 2023; 53: 327-34.

[10]

Olsen RW. GABAA receptor: Positive and negative allosteric modulators. Neuropharmacology. 2018; 136: 10-22.

[11]

Betlazar C, Middleton RJ, Banati R, Liu GJ. The Translocator Protein (TSPO) in Mitochondrial Bioenergetics and Immune Processes. Cells. 2020; 9: 512.

[12]

Sparrow EL, James S, Hussain K, Beers SA, Cragg MS, Bogdanov YD. Activation of GABA(A) receptors inhibits T cell proliferation. PLoS One. 2021; 16: e0251632.

[13]

Falcón CR, Hurst NF, Vivinetto AL, López PHH, Zurita A, Gatti G, et al. Diazepam Impairs Innate and Adaptive Immune Responses and Ameliorates Experimental Autoimmune Encephalomyelitis. Front Immunol. 2021; 12: 682612.

[14]

Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax. 2013; 68: 163-70.

[15]

Oh TK, Park HY, Han JY, Song IA. Prior benzodiazepine use and mortality among adult patients with sepsis: A retrospective population-based cohort study in South Korea. Int J Clin Pract. 2021; 75:e14517.

[16]

Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2022; 185: 576.

[17]

Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front Oncol. 2021; 11: 617335.

[18]

Cornwell AC, Tisdale AA, Venkat S, Maraszek KE, Alahmari AA, George A, et al. Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer. Clin Cancer Res. 2023; 29: 3793-812.

[19]

Registri farmaci sottoposti a monitoraggio [Internet]. Agenzia Italiana del Farmaco; c2024 [cited 2024 Sep 30]. Available from: https://www.aifa.gov.it/registri-farmaci-sottoposti-a-monitoraggio

[20]

PD-L1 IHC 22C3 pharmDx [Internet]. Agilent Technologies, Inc; c2024 [cited 2024 Sep 30]. Available from: https://www.agilent.com/en/product/pharmdx/pd-l1-ihc-22c3-pharmdx

[21]

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4: 351-7.

[22]

Benzodiazepine derivatives [Internet]. PharmGKB; c2024 [cited 2024 Sep 30]. Available from: https://www.pharmgkb.org/chemical/PA10402

[23]

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. ; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18: e143-52.

[24]

Wang X, Ji X. Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies. Chest. 2020; 158: S12-20.

[25]

Zhang Z, Kim HJ, Lonjon G, Zhu Y ; written on behalf of AME Big-Data Clinical Trial Collaborative Group. Balance diagnostics after propensity score matching. Ann Transl Med. 2019; 7: 16.

[26]

The R project for statistical computing [Internet]. The R Foundation; c2024 [cited 2024 Sep 30]. Available from: https://www.r-project.org

[27]

Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016; 375: 2293-7.

[28]

Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006; 163: 1149-56.

[29]

Pizzutilo EG, Romanò R, Roazzi L, Agostara AG, Oresti S, Zeppellini A, et al. Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity. Cancer Res. 2023; 83: 2283-96.

[30]

Chen J, Chen S, Luo H, Long S, Yang X, He W, et al. The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review. Int Immunopharmacol. 2023; 124: 110919.

[31]

Li H, Zhang L, Yang F, Zhao R, Li X, Li H. Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review. Front Immunol. 2023; 14: 1218386.

[32]

Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, et al. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clin Lung Cancer. 2021; 22: e57-62.

[33]

Montégut L, Derosa L, Messaoudene M, Chen H, Lambertucci F, Routy B, et al. Benzodiazepines compromise the outcome of cancer immunotherapy. Oncoimmunology. 2024; 13: 2413719.

[34]

Wiley SZ, Sriram K, Salmerón C, Insel PA. GPR68: An Emerging Drug Target in Cancer. Int J Mol Sci. 2019; 20: 559.

[35]

O’Hayre M, Degese MS, Gutkind JS. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 2014; 27: 126-35.

[36]

Lynch JR, Wang JY. G Protein-Coupled Receptor Signaling in Stem Cells and Cancer. Int J Mol Sci. 2016; 17: 707.

[37]

Xu J, Mathur J, Vessières E, Hammack S, Nonomura K, Favre J, et al. GPR68 Senses Flow and Is Essential for Vascular Physiology. Cell. 2018; 173: 762-75.e16.

[38]

Cao L, Li W, Yang X, Zhang W, Li M, Zhang H, et al. Inhibition of host Ogr1 enhances effector CD8+ T-cell function by modulating acidic microenvironment. Cancer Gene Ther. 2021; 28: 1213-24.

[39]

Ye S, Zhu Y, Zhong D, Song X, Li J, Xiao F, et al. G protein-coupled receptor GPR68 inhibits lymphocyte infiltration and contributes to gender-dependent melanoma growth. Front Oncol. 2023; 13: 1202750.

[40]

Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, et al. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023; 11: e007310.

[41]

Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023; 4: 100878.

[42]

Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022; 40: 509-23.e6.

[43]

Poth KJ, Guminski AD, Thomas GP, Leo PJ, Jabbar IA, Saunders NA. Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma. Mol Cancer Ther. 2010; 9: 2430-9.

[44]

Kiss E, Abdelwahab EHMM, Steib A, Papp E, Torok Z, Jakab L, et al. Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner. Respir Res. 2020; 21: 120.

[45]

Cao P, Wang Y. Effect of pemetrexed on the efficacy, toxic reaction, and survival rate of patients with EGFR-TKI resistant moderate and advanced lung cancer. Am J Transl Res. 2021; 13: 7857-65.

[46]

Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004; 25: 94-102.

PDF (2233KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉